BridgeBio Pharma, Inc. (BBIO) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Palo Alto, CA, United States. The current CEO is Eric Michael David.
BBIO has IPO date of 2019-06-27, 725 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $15.11B.
BridgeBio Pharma, Inc. is a biopharmaceutical company focused on discovering, developing, and delivering medicines for genetic diseases. The company maintains a pipeline of 30 development programs spanning early-stage discovery through late-stage clinical development, including product candidates such as AG10 for TTR amyloidosis-cardiomyopathy, BBP-831 for pediatric achondroplasia, BBP-631 for congenital adrenal hyperplasia, and Encaleret for autosomal dominant hypocalcemia. BridgeBio's therapeutic focus extends across rare genetic disorders, oncology, and gene therapy, supported by collaboration agreements with leading academic institutions including Stanford University and the University of California. Founded in 2015 and headquartered in Palo Alto, California, the company leverages both small molecule and gene therapy approaches to address unmet medical needs in Mendelian and genetic disease markets.
